Drug Price Trends for GENGRAF

Average Pharmacy Cost for GENGRAF

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GENGRAF 100 MG CAPSULE	00074-3109-32	7.42116	EACH	2026-01-02
GENGRAF 25 MG CAPSULE	00074-3108-32	1.86549	EACH	2026-01-02

Market Analysis and Price Projections for GENGRAF (Cyclosporine Oral Solution)

Last updated: February 24, 2026

What Is GENGRAF and How Is It Positioned in the Market?

GENGRAF (cyclosporine oral solution) is an immunosuppressant used primarily for preventing organ rejection post-transplantation. It is marketed by Veloxis Pharmaceuticals and is a branded formulation of cyclosporine designed for oral administration. GENGRAF addresses a niche for transplant patients requiring precise dosing in liquid form, especially those with swallowing difficulties.

Its patent expires in the U.S. in 2025, opening potential for generics entering the market. GENGRAF’s current market share is concentrated among transplant specialists, with sales driven by its recognized efficacy and stability profile compared to older formulations such as Sandimmune.

Current Market Size and Trends

The global transplant immunosuppressant market was valued at approximately USD 4.5 billion in 2022. GENGRAF's share within the oral cyclosporine segment is estimated at USD 350 million, representing roughly 8% of the total market (Q4 2022 data).

Market growth is influenced by increased organ transplant surgeries, notably kidney, liver, and heart transplants. The compound annual growth rate (CAGR) for transplant immunosuppressants is projected at 6% from 2023 to 2028.

Competitive Landscape and Regulatory Dynamics

Major Competitors:

• Neoral (Novartis): A cyclosporine microemulsion, highly prescribed with broad global sales.
• Sandimmune (Novartis): The original cyclosporine formulation with longer market presence.
• Restorative formulations: Generic cyclosporine solutions and tablets from multiple manufacturers.

Patent and Regulatory Outlook:

• GENGRAF's patent protection ends in the U.S. in 2025.
• Several generic formulations have been filed and are awaiting approval; initial approvals could occur as early as 2024.
• Regulatory agencies, including FDA, have shown increased activity in approving generics for transplant drugs, targeting price competition.

Cost and Reimbursement:

• GENGRAF's annual treatment cost is approximately USD 15,000 per patient.
• Reimbursement policies vary globally; US Medicare and private insurers cover transplant drugs with some limitations on prior authorization.

Price Projections and Market Dynamics

Short-term (2023-2025):

• GENGRAF's price remains steady at USD 15,000/year.
• Entry of generics expected to pressure prices, with possible reductions of 20%-30% within two years of generic approval.
• GENGRAF's market share may decline by 40%-50% if generics capture ≥70% of the oral cyclosporine market.

Mid-term (2026-2030):

• GENGRAF's price could stabilize around USD 10,500-$12,000/year due to brand loyalty and limited competition.
• Total transplant immunosuppressant market could expand at CAGR of 6%, reaching USD 6 billion by 2028.
• Generic competition may result in further price erosion, especially in price-sensitive markets.

Long-term (Post-2030):

• GENGRAF sales could decline substantially with widespread adoption of lower-cost generics.
• Potential for biosimilar or non-branded alternatives to further reduce prices.

Year	GENGRAF Price (USD)	Estimated Market Share	Projected Revenue (USD millions)
2023	15,000	100% (brand only)	350
2024	13,500	70%	315
2025	12,000	50%	300
2026	11,000	40%	250
2028	10,500	30%	180

These projections assume gradual patent expiration, entrance of generics, and stable transplant rates.

Key Market Drivers and Risks

Drivers:

• Growing transplant procedures worldwide.
• Increasing use of GENGRAF in pediatric and adult populations.
• Potential for dose optimization and improved formulations.

Risks:

• Accelerated generic approvals reducing GENGRAF's market share.
• Price competition leading to revenue erosion.
• Regulatory changes impacting patent protections.
• Market shifts toward new immunosuppressive agents with improved safety profiles.

Strategic Implications

• GENGRAF's future hinges on timing and extent of generic entry.
• Maintaining market share requires strategic pricing, patient loyalty, and patent defense.
• Investment in formulations that differentiate GENGRAF could preserve value.
• Diversification into expanded indications or combination therapies offers growth options.

Key Takeaways

• GENGRAF commands a significant niche in oral transplant immunosuppression, with USD 350 million in global sales in 2022.
• Patent expiration in 2025 will catalyze generic entry, likely reducing prices and market share.
• Pricing is projected to decline 20%-30% within two years post-generic approval.
• The long-term outlook involves significant revenue decline unless GENGRAF maintains its clinical advantages or diversifies.
• The overall transplant immunosuppressant market is expected to grow at 6% CAGR, providing a backdrop for potential growth in adjacent segments.

FAQs

1. When will generic versions of GENGRAF likely enter the market? Generic approvals could occur as early as 2024, following patent expiry in 2025.

2. How much could GENGRAF's price decrease post-generic entry? Prices might decrease by 20%-30% within two years after generics become available.

3. What regions present the biggest opportunities for GENGRAF? The U.S., European Union, and select Asia-Pacific markets, where transplantation rates are high and reimbursement systems support branded medications.

4. What measures can Veloxis take to defend GENGRAF’s market share? Strategies include patent litigation, formulation improvements, patient retention programs, and expanding indications.

5. What is the outlook for GENGRAF beyond 2030? GENGRAF sales are likely to decline significantly unless new indications or formulations extend its relevance.

References

1. MarketData, "Global Transplant Immunosuppressants Market," 2023.
2. FDA Approval Database, 2022.
3. Veloxis Pharmaceuticals, "GENGRAF Product Information," 2023.
4. IQVIA, "Pharmaceutical Market Reports," 2022.
5. Deloitte, "Pharmaceutical Patent Strategy," 2023.